Partner Identity

Tecnalia Serbia Ltd. (TECSR) is a Belgrade-based research and innovation company fully owned by Fundación Tecnalia Research & Innovation (TECNALIA), one of Europe's leading applied research organisations. Founded in 2008, Tecnalia Serbia acts as a technology acceleration unit within TECNALIA's Health business unit, specialising in biomedical instrumentation, bioelectronic systems, and advanced medical technologies.

The team has been involved in over ten EU-funded research projects under the H2020 and Horizon Europe programmes, leading developments in electrophysiological and electrochemical sensing, electrical stimulation, and system integration. Tecnalia Serbia collaborates closely with a number of universities, hospitals, and rehabilitation clinics in the region, enabling early validation and efficient transfer of research outcomes to industrial and clinical applications.

Through several coordination and support actions focused on the biomedical technology research and innovation community, Tecnalia Serbia has forged strong relationships with key stakeholders across the four components of the quadruple helix.

Role in PHOENIX

In PHOENIX, TECNALIA Serbia (TECSR) contributes to extending the project's organs-on-chip technologies toward scalable and industry-ready cardiac safety applications. TECSR leads the development of µSafeHeart, a simplified cardiac screening platform based on screen-printed multielectrode arrays integrated into multiwell plates.

The platform enables electrical stimulation and real-time recording of field potentials and impedance from 3D cardiac microtissues, while remaining fully interoperable with PHOENIX instrumentation. In addition, TECSR is responsible for prototyping, testbed development, and process scale-up, including the assessment of near-shore manufacturing in Southeast Europe. Through these activities, TECSR strengthens PHOENIX's exploitation potential, industrial relevance, and widening impact.

Main contributions and activities:

• Design, prototyping, and integration of screen-printed multielectrode arrays for the µSafeHeart cardiac safety platform
• Development of testbeds, interfaces, and scalable manufacturing processes, including near-shore production assessment
• Support to exploitation, dissemination, and capacity-building activities in widening countries, enhancing uptake of PHOENIX technologies

Technologies and Facilities